R. Huber

发表

Prevalence and risk factors of brain metastases in patients with newly diagnosed advanced non-small-cell lung cancer

A. Morresi‐Hauf, V. Zietemann, S. Kappler, 2015 .

Topotecan in Second-Line Therapy of SCLC: Impact on Survival?

J. von Pawel, U. Gatzemeier, J. Mezger, 2000, Oncology Research and Treatment.

Basal HIF-1α expression levels are not predictive for radiosensitivity of human cancer cell lines

M. Molls, P. Vaupel, G. Multhoff, 2012, Strahlentherapie und Onkologie.

Chronic progressive HIV-1 infection is associated with elevated levels of myeloid-derived suppressor cells

R. Draenert, J. Bogner, T. Vollbrecht, 2012, Retrovirology.

Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLC.

S. Barni, R. Ramlau, M. Mitrović, 2005, Lung cancer.

Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancer

J. von Pawel, M. Reck, J. Mezger, 2006, European Respiratory Journal.

The revised GOLD 2017 COPD categorization in relation to comorbidities

J. Vestbo, F. Biertz, H. Watz, 2018, Pneumologie.

Chronic progressive HIV-1 infection is associated with elevated levels of myeloid-derived suppressor cells

R. Draenert, J. Bogner, T. Vollbrecht, 2012, Retrovirology.

823 A full navelbine oral (NVB oral) treatment in combination with cisplatin (P) followed by NVB oral single agent as consolidation therapy in advanced non small-cell lung cancer (NSCLC)

S. Barni, R. Ramlau, M. Mitrović, 2003 .

Correlation between dihydropyrimidine dehydrogenase and efficacy and toxicity of fluoropyrimidine drugs.

R. Huber, M. Zhuang, Huber Rm, 2014, European review for medical and pharmacological sciences.